![conference banner](/images/conference-banner.jpeg)
Abstract
Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung loss. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current standard for the treatment for AAT deficiency. While therapy with pooled AAT is the cornerstone of treatment in patients with AAT deficiency, patients should also benefit from proven treatments for other obstructive lung diseases like chronic obstructive pulmonary disease (COPD). Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics should be viewed as essential therapies in the management of AAT deficiency.
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Utilization of Proven Therapies for Chronic Obstructive Lung Disease (COPD) in Patients with Alpha-1 Antitrypsin Deficiency
Volume: 10 Issue: 5
Author(s): Amit Mahajan and D. Kyle Hogarth
Affiliation:
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Abstract: Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung loss. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current standard for the treatment for AAT deficiency. While therapy with pooled AAT is the cornerstone of treatment in patients with AAT deficiency, patients should also benefit from proven treatments for other obstructive lung diseases like chronic obstructive pulmonary disease (COPD). Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics should be viewed as essential therapies in the management of AAT deficiency.
Export Options
About this article
Cite this article as:
Mahajan Amit and Kyle Hogarth D., Utilization of Proven Therapies for Chronic Obstructive Lung Disease (COPD) in Patients with Alpha-1 Antitrypsin Deficiency, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (5) . https://dx.doi.org/10.2174/1871523011109050368
DOI https://dx.doi.org/10.2174/1871523011109050368 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Coronary Magnetic Resonance Imaging
Current Pharmaceutical Design Cells and Mediators of Inflammation in Acute Pancreatitis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Impact of Cerebral Oxygen Saturation Monitoring on Short-term Neurodevelopmental Outcomes in Neonates with Encephalopathy - A Prospective Cohort Study
Current Pediatric Reviews Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
Current Pharmaceutical Biotechnology Extracellular RNA, a Potential Drug Target for Alleviating Atherosclerosis, Ischemia/Reperfusion Injury and Organ Transplantation
Current Pharmaceutical Biotechnology Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Propofol Pharmacokinetics in Patients with Obstructive Jaundice
Current Drug Delivery Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry [General Articles] Natriuretic Peptides in Alcohol Withdrawal: Central and Peripheral Mechanisms
Current Medicinal Chemistry The Role of Anticoagulation in IPF
Current Respiratory Medicine Reviews Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Gene Therapy for Type I Glycogen Storage Diseases
Current Gene Therapy Chinese Medicine in Inhalation Therapy: A Review of Clinical Application and Formulation Development
Current Pharmaceutical Design Systemic Sclerosis Associated Interstitial Lung Disease
Current Respiratory Medicine Reviews Redox State, Oxidative Stress, and Molecular Mechanisms of Protective and Toxic Effects of Bilirubin on Cells
Current Pharmaceutical Design A Review of the Current Role of Proton Therapy in Modern Oncology
Current Drug Therapy Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets